<DOC>
	<DOCNO>NCT02091505</DOCNO>
	<brief_summary>Recent study show intravitreal injection anti-VEGF agent , Lucentis ( Ranibizumab ) effective macular edema associate central retinal vein occlusion ( CRVO ) . However , little information whether predictive factor treatment outcome treatment . We plan perform comprehensive functional imaging test determine significant predictive factor .</brief_summary>
	<brief_title>Predictive Factors Ranibizumab Treatment Macular Edema With CRVO</brief_title>
	<detailed_description>The purpose present study investigate predictive factor treatment outcome intravitreal injection Lucentis ( Ranibizumab ) eye macular edema associate central retinal vein occlusion ( CRVO ) use various comprehensive clinical test include visual file , spectral-domain optical coherence tomography ( SD-OCT ) , ultra wide-field fluorescein angiography , new flicker electroretinogram ( ERG ) use skin electrode . Corrected visual acuity , visual file , spectral-domain optical coherence tomography ( SD-OCT ) , ultra wide-field fluorescein angiography , new flicker electroretinogram ( ERG ) use skin electrode perform 3 , 6 , 9 , 12 month treatment . Predictive factor treatment outcome statistically analyze .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Macular edema associate central retinal vein occlusion Best correct visual acuity &lt; 20/30 Central macular thickness &gt; 300 Period symptom onset treatment &lt; 12 month Any past history treatment macular edema ( e.g . antiVEGF injection , steroid , vitrectomy )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>